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ABSTRACT
Context: Healthcare facilities in developing countries are over burdened and proper triage of patients requiring attention 
more than others is needed in every sub speciality of medical sciences in them. Patients with pre‑eclampsia require attention 
to prevent any associated complication. 
Aims: The aim of this study was to evaluate whether hsCRP alone or in combination could be used as an indicator of severity 
and predictor of outcome in women with PE presenting to a healthcare facility late in the third trimester. 
Settings and Design: Prospective observational study conducted at a teaching medical college and referral hospital catering 
primarily to rural, semi urban and tribal population. 
Methods and Material: 85 women with PE who reported to the hospital after completed 36 weeks of gestation were included. 
Patients were divided in three groups. hsCRP, biochemical and hematological investigations were performed for each patient. 
Results were expressed as median. Independent samples Kruskall Wallis one way ANOVA and Mann Whitney U tests were 
performed and correlation of hsCRP with other parameters and fetal outcome was examined. 
Statistical Analysis Used: Kruskall Wallis one way ANOVA and Mann Whitney U tests. 
Results: hsCRP was significantly elevated in severe PE as compared to PE without severe features and normal patients. Higher 
requirement of labour induction and caesarean section was seen in severe PE patients along with higher still births and low baby 
weight babies. hsCRP had positive correlation with other markers of severity of PE and negative correlation with still births and fetal 
weight in severe PE patients. However, although raised in every case of severe PE, a wide variation was noted in hsCRP values. 
Conclusions: hsCRP alone cannot be recommended as a marker of severity or a predictor of outcome in women presenting 
late in the third trimester of pregnancy. However, in combination with serum uric acid it can be used for that purpose.
Key words: Diastolic blood pressure; hsCRP; Pre‑eclampsia; serum uric acid; still births.
Introduction
Pre-eclampsia (PE) is an important complication of pregnancy 
affecting about 2-8% of all pregnancies.[1,2] PE is believed to 
be a leading cause of maternal, peri-natal morbidity, and 
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mortality.[3] Around 10–15% of maternal deaths are associated 
with PE and eclampsia.[2] PE affects women in both developed 
and developing countries, but the maternal mortality is 
much lower in the developed countries.[3] PE may lead to 
eclampsia, HELLP syndrome, central nervous system, renal, 
and pulmonary complications.[2]
PE is diagnosed based on clinical presentation, detailed 
examination, and blood pressure measurements. 
Hematological and biochemical investigations have been 
historically used for prognostication of severity of PE. While 
clinical examination, blood counts, liver function test, 
renal function test, ultrasonography along with uterine 
artery Doppler[4] help in diagnosis of HELLP syndrome 
and other complications of PE,[2] serum uric acid levels,[5,6] 
circulating angiogenic factors like soluble Fms-like tyrosine 
kinase -1 (sFlt-1) and placental growth factor (PlGF)[7] contribute 
in predicting adverse fetal-maternal outcome. These have 
been proposed to be used as indicators of the severity of PE 
and adverse maternal-fetal outcomes.[7] The greatest utility 
of these markers is to predict the progression of gestational 
hypertension to PE. However, negative predictive values of 
these markers are low and recommendations for their use 
can’t be made based on the available evidence.
PE is believed to progress in two stages.[3] Placental stage[3,8] 
includes atypical maternal immune response to trophoblasts 
with either impaired decidualization or failure of proper 
uterine preconditioning.[3] Vascular endothelial growth 
factor (VEGF), placental growth factor (PlGF), Soluble 
Fms-like tyrosine kinase -1(sFlt-1), Soluble endoglin (sEng), 
Pregnancy-associated plasma protein-A (PAPP-A) and 
Neutrophil gelatinase-associated lipocalin (NGAL) are few 
biomarkers with utero-placental origin which are under 
investigation in PE.[9] These investigations are useful till 
34 weeks of pregnancy. They are expensive and are not 
widely available.
The second stage has been found to be associated with 
an inflammatory state.[3,8] Markers of inflammation like 
C-reactive protein (CRP) is postulated to be raised in PE and 
may be used as indicator of severity of PE.[10,11] Highly sensitive 
CRP assay (hsCRP) has become popular due to its ability to 
detect very low concentrations of CRP[12,13] and its acceptance 
as a predictor of cardiovascular disease.[14] Measurement of 
hsCRP can be done using the blood sample which is routinely 
drawn for the hematological investigations.
In developing countries, symptoms of PE are often neglected 
or missed, and it is not uncommon for pregnant women 
to present to a hospital for the first time late in the third 
trimester or in early labor with PE. These are the patients 
who have never visited any hospital during their entire 
pregnancy. The tertiary hospitals in developing countries 
are invariably overburdened. Simple, reliable and easy to 
interpret investigation which could help in identification 
of patients requiring greater attention over others is often 
desired.
The study aimed to evaluate whether hsCRP could be used 
alone on its own as an effective indicator of severity and 
predictor of outcome of PE in pregnant women presenting 
for the very first time to a healthcare facility in the late third 
trimester. Additionally, correlation of hsCRP with the currently 
available investigations was also done.
Subjects and Methods
This was a prospective observational study which was 
conducted at a Medical college hospital in India over 
two years after obtaining institutional ethical committee 
clearance. All pregnant women presenting to the hospital for 
the first time after completed 36 weeks of pregnancy were 
included. Patients with singleton pregnancy with no obvious 
foci of infection, non-smokers, those with a body mass index 
(BMI) of less than 30, those who didn’t have any history of 
cardiac disease or prior hypertension and who consented 
for participation were included. While those who were in 
active labor, those who had history of prior hypertension, 
BMI <15 or >30, smokers, those with any focus of infection, 
Pre-Mature Rupture of Membranes (PROM), any other chronic 
disease and those who were on steroids.
After physical and obstetric examination presence of 
urinary protein was detected by dipstick. Patients with 
systolic blood pressure  (SBP) ≥140 mmHg and diastolic 
blood  pressure  (DBP)  ≥90 mmHg,  measured  on  two 
occasions 6 hours apart with presence of proteinuria 
on dipstick (minimum 1+) were considered to have PE. 
Patients with PE were further sub-divided into PE without 
severe features (SBP <160 mmHg and/or DBP >90 mmHg 
but <110 mmHg) and severe PE (SBP ≥160 mmHg and/or 
DBP ≥110 mmHg). Height and weight of all the patients 
were measured. Totally, 10 ml blood was drawn from 
the ante-cubital vein at the time of admission and sent 
for estimation of hemoglobin, total leukocyte count, 
total platelet count, serum bilirubin, serum glutamic 
oxaloacetic transaminase (SGOT), serum glutamic pyruvic 
transaminase (SGPT), blood urea, serum creatinine, 
serum uric acid and hsCRP. hsCRP was estimated using 
the immuno-nephelometric method. hsCRP value 
between 0 and 5 mg/dl was considered to be within 
normal limits. Values more than or equal to 5 mg/dl 
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were taken as elevated. All patients underwent obstetric 
ultrasonography. Fetal parameters and uterine artery 
doppler were done.
Patients were managed as per departmental protocol and 
regular monitoring was done aimed at ensuring maternal 
and fetal well-being. Anti-hypertensive agents were started 
based on existing guidelines and the protocol followed in 
the department. In all patients with PE presenting at or after 
completed 37 weeks, labor was either induced or augmented 
depending on the clinical assessment. Caesarean section 
was performed for either maternal or fetal indications. 
Post-delivery status of the child (live-born or stillborn), 
placental weight, and baby weight were recorded.
The data was analyzed using SPSS version 20 (IBM analytics, USA). 
Shapiro-Wilk test was used to check whether the data was 
normally distributed. The results were expressed as median. 
Comparison of nominal data with respect to hsCRP was done 
using cross tabs and Chi-square test. Independent samples 
Kruskall Wallis one-way ANOVA was used to compare the 
results across the three groups for non-parametric data. In 
case a statistically significant difference was found in any 
of the parameters, further comparison between the groups 
was done by Mann Whitney test. Spearman’s correlation was 
calculated between hsCRP and the rest of the other parameters 
under investigation. For all the tests, a “P” value of < 0.05 
was considered statistically significant.
Results
Eighty-five patients were included in the study. Forty patients 
had uneventful pregnancy, 33 patients had severe PE and 
12 patients had PE without severe features. The median 
values of various parameters as well as the P values of the 
non-parametric tests used are summarized in Table 1.
Serum uric acid levels were significantly different between 
normal and severe PE, normal, and PE without severe feature 
groups as well as PE without severe feature and severe PE 
groups (P values 0.00, 0.00, and 0.029, respectively). hsCRP 
levels were found to be statistically significantly different 
between normal and severe PE and normal and PE without 
severe feature groups (P values 0.00 and 0.00). However, 
hsCRP levels were not significantly different between PE 
without severe feature and severe PE groups (P value 0.275). 
hsCRP was more than or equal to 5 mg/L in 23 out 33 patients 
with severe PE; thus, the sensitivity of hsCRP in detecting 
severe PE patients was 69.7%. Its specificity was 87.5% (35 
out of 40 normal patients had hsCRP <5 mg/L).
Uterine artery doppler study details have been summarized 
in Table 1. No significant difference was found between 
normal and PE without severe features (P value 0.488), 
normal and severe PE (P value 0.573) and PE without severe 
features and severe PE (P value 0.261) groups in the Doppler 
studies.
Table 1: Table showing the median values of clinical, hematological, and biochemical parameters for the three study groups




Pre eclampsia without 
severe feature group (n=12)
P (independent sample 
Kruskall Wallis test)
Age in years 21 (20‑30) 23 (18‑35) 21.5 (20‑30) 0.056
Gestational age in weeks 39.8 (37‑41) 38.5 (37‑40.5) 38.7 (38‑40) 0.069
Weight in kg 64 (55‑70) 62 (48‑68) 59 (50‑65) 0.011
Height in meters 1.54 (1.47‑1.65) 1.54 (1.44‑1.62) 1.52 (1.44‑1.54) 0.037
Body mass index 26.84 (23.4‑29.4) 26.37 (22.5‑28.6) 25.20 (22.5‑28.1) 0.038
SBP (mm Hg) 117 (100‑130) 170 (150‑220) 150 (150‑160) 0.00
DBP (mm Hg) 76 (60‑90) 120 (110‑190) 100 (96‑108) 0.00
MAP (mm Hg) 90 (73.3‑98.7) 136.6 (123.3‑200) 116.6 (116.6‑120) 0.00
Haemoglobin (g/dl) 10.7 (9.2‑14.0) 12 (6.4‑14) 11 (10‑12) 0.03
Total Leukocyte count (/ml) 10,100 (7,600‑12,600) 12,100 (9,800‑15,000) 10,800 (10,000‑11,800) 0.00
Total platelet count (×105/ml) 2.5 (1.8‑3.2) 2.2 (1.8‑4.10) 2.15 (1.8‑3.10) 0.015
SGOT (U/L) 34 (23‑55) 70 (29‑90) 42 (30‑88) 0.00
SGPT (U/L) 33 (11‑50) 56 (18‑88) 41 (30‑90) 0.00
Serum bilirubin (mg/dl) 0.8 (0.2‑1.6) 1.2 (0.6‑2) 1.05 (0.6‑1.6) 0.00
Blood urea (mg/dl) 30 (18‑50) 47 (18‑90) 38 (24‑88) 0.00
Serum creatinine (mg/dl) 0.8 (0.3‑2.2) 1.3 (0.7‑9.0) 1 (0.8‑2) 0.00
Serum uric acid (mg/dl) 3.95 (2.4‑8.0) 8.6 (5‑15) 5.9 (4.2‑12) 0.00
hsCRP (mg/L) 2.25 (1.1‑7.6) 6.2 (2.5‑26.2) 5.3 (2.8‑12.4) 0.00
Uterine artery doppler S/D ratio N 31, R 6, A 3 N 23, R 5, A 5 N 11, R1, A 0
SBP, DBP, and MAP stand for systolic blood pressure, diastolic blood pressure, and mean arterial pressure, respectively. S/D ratio stands for systolic flow to diastolic flow ratio. N, R, 
and A stand for Normal, Reversed, and Absent, respectively
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The need for induction of labor, mode of delivery, fetal 
outcome, baby weight, and placental weight during 
pregnancy has been summarized in Table 2. Chi-square 
test showed a significant difference (P value 0.009) in the 
number of women requiring labor induction in severe 
PE group as compared to normal and between women 
with severe PE and PE without severe features groups 
(P value 0.035). There was no significant difference in 
the number of women undergoing caesarean section 
and vaginal delivery between any of the three groups. 
A significant difference was noted in the number of women 
delivering still born fetuses in severe PE group as compared 
to normal (P value 0.011) but no significant difference was 
found in still births between normal and PE without severe 
features as well as severe and PE without severe features 
groups (P values 0.065 and 0.552, respectively).
Weight of the babies and the placentas were not found to 
be statistically different across the three study groups by the 
Kruskall Wallis test [Table 2] with the P values being 0.948 
and 0.078, respectively.
Patients with PE without severe features had a positive 
correlation of hsCRP with DBP, serum bilirubin and serum 
uric acid level (P values 0.016, 0.034, and 0.029, respectively). 
In patients with severe PE however, significantly positive 
correlation between hsCRP and SBP, DBP, MAP, TLC, SGOT, 
SGPT, serum bilirubin, blood urea, serum creatinine, 
serum uric acid, and S/D ratio was noted. A negative 
correlation between hsCRP and baby weight was found. 
Figures 1 and 2 show the positive and negative correlation of 
hsCRP with the DBP and baby weight. There was no maternal 
mortality in any of the groups.
Table 2: Table summarizing the events around delivery in the women of the three groups
Parameters Normal pregnancy group Severe pre‑eclampsia group Pre‑eclampsia without severe features group
Induction of 
labor
Not required 28 13 9
Required 12 20 3
Mode of 
delivery
Vaginal delivery 24 16 6
Caesarean section 16 17 6
Fetal outcome Live birth 40 28 11
Still birth 0 5 1
Baby weight (kg) 2.5 (1.9‑3.5) 2.39 (1.0‑3.5) 2.45 (1.5‑4.0)
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Discussion
Pre-eclampsia is characterized by new-onset hypertension 
detected after 20 weeks of gestation which adversely affects 
both the mother and fetus. New onset proteinuria, symptoms 
of headache, visual disturbances, epigastric pain, vomiting 
are the symptoms which should heighten suspicion of PE. 
Pregnant women often do not seek timely medical care in 
many developing countries due to numerous factors. Quite 
often these patients turn up late in the third trimester with 
multiple issues to a healthcare facility, which themselves 
are often overburdened with patients. Late presentation 
often precludes proper management and can contribute to 
increased maternal and perinatal complications. Explanation 
of prognosis of complications to the patient and her relatives 
is crucial in management of these late presenting cases. 
Simple markers which can help in prognostication are 
constantly under investigation of researchers. Prognostic 
markers which can quickly and accurately predict the severity 
and possibility of adverse outcomes could be useful as a 
guide for management. As it is believed that a systemic 
inflammatory response is associated with pregnancy, CRP 
could play a role in defining the severity of PE and has 
been investigated as a marker previously. This study was 
conceptualized and conducted to evaluate whether hsCRP 
alone can be used as an indicator replacing the battery of 
other tests in patients who have presented to a healthcare 
facility for the very first time in her entire pregnancy in the 
late third trimester.
In the present study, patients were of comparable age and 
had similar gestational age at presentation. BMI of patients 
was comparable. Women in the normal group had the 
different parameters under study within acceptable limits and 
there were no still births in these patients. Patients with PE 
without severe features had similar values of hematological 
parameters but had raised values of bilirubin, serum 
creatinine, and blood urea when compared to the normal 
group. The hsCRP levels were significantly raised in these 
patients when compared to women with normal pregnancy. 
Caesarean section was performed in 50% of such cases and 
there was one still birth. The median baby weight was similar 
to the normal group.
Women with severe PE had significant differences in SBP, DBP, 
and MAP compared to both the normal and those with PE 
without severe features patients. The biochemical parameters 
including hsCRP and uric acid were also significantly different 
between severe PE, normal and PE without severe features 
groups. Requirement of induction of labor and rate of 
caesarean section was higher in the women with severe PE. 
The number of still births in women with severe PE was more 
as compared to those with normal pregnancy and PE without 
severe features groups. However, the difference among the 
baby weight and the weight of placenta between these groups 
was not statistically significant.
Correlation analysis showed positive correlation of hsCRP 
with SBP, DBP, MAP, TLC, SGOT, SGPT, serum bilirubin, blood 
urea, serum creatinine, serum uric, and a significant negative 
correlation between hsCRP and baby birth in women with 
severe PE. Additionally, in women with severe PE there was a 
negative correlation between hsCRP and placental weight, but 
it was not statistically significant. Moreover, blood pressure 
measurements, and biochemical parameters like SGOT, SGPT, 
TLC, serum bilirubin, and serum uric acid had significant 
negative correlation with baby weight in severe PE but not 
in any other group.
Many previous studies have examined the role of CRP/hsCRP 
as a marker of severity of PE. Table 3 summarizes these studies 
which were obtained through a literature search. Teran et al.[15] 
Belo et al.[17] Utsun et al.[11] Batashki et al.[19] and Deveci et al.[21] 
have found that CRP levels were elevated in PE. Savvidou et al.[16] 
however reported that PE may not be preceded by a maternal 
inflammatory response when the CRP levels were used as an 
indicator. Kumru et al.[18], Gandevani et al.[22] and Farzadnia el 
al.[23] used hsCRP as a marker and found it to be raised in PE. 
Gandevani et al.[22] had the largest number of patients and found 
that hsCRP could be useful in identifying pregnant women at risk 
for PE. Notably though, they studied pregnant women between 
14 and 20 weeks of gestation and did not actually study patients 
with diagnosed PE. Their study was focused on evaluating the 
predictive capability hsCRP in the mid trimesters of pregnancy. 
A wide variation in the CRP levels has been pointed out by 
Belo et al.[17] We too noted that while hsCRP levels were raised 
in patients with PE, with the hsCRP values being significantly 
more in patients with severe PE as compared to normal patients, 
the actual values have wide variations (range of 2.5–26.2 mg/
dl), which means that absolute numerical value of hsCRP is not 
proportionate to the severity of PE. Thus, a patient may have 
severe PE but her hsCRP level might not be elevated. In the 
present study the sensitivity and specificity of hsCRP was 69.7% 
and 87.5% respectively for detecting patients with severe PE. 
This in our view makes it difficult to recommend hsCRP as the 
sole investigation for prognostication in women presenting late 
in third trimester. In other words, although hsCRP level might 
be increased in a patient of PE but that value alone might not 
predict the severity. However, we believe that when combined 
with blood pressure records and serum uric acid measurements, 
hsCRP can be used with reasonable confidence for predicting 
severity and for prognostication. While the role of uric acid 
as a predictor was earlier questioned,[5] the Task Force on 
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Table 3: Table summarizing the studies on CRP/hsCRP as an indicator of severity of Pre‑eclampsia and a comparison with the 
current study













CRP and pro‑inflammatory cytokines are present in 







45 patients each with
Normal and abnormal 
uterine doppler
CRP PE may not be preceded by a maternal inflammatory 
response, as assessed by measurement of CRP
Belo et al.
(2005)[17]
Portugal Longitudinal 23 pregnant women
24 nulliparous women
CRP, total and differential 
leukocyte count, GM‑CSF, 
Lactoferrin, Elastase
Changes in CRP levels vary in a wide manner between 





26 healthy pregnant 
women, 26 mild PE and 
26 severe PE women
CRP, Plasma fibrinogen Elevated level of CRP and fibrinogen in PE.






20 healthy pregnant 






Serum hsCRP levels increase in women with PE which 





30 women with PE and 
30 women with normal 
pregnancy




South Korea Longitudinal 25 PE women, 202 
healthy pregnant 
women in 4 groups
hsCRP, biochemical 
investigations, MAP, uterine 
artery S/D ratio
hsCRP levels positively correlate to pregnancy duration in 
healthy women and could be used as a severity marker 





67 women with PE and 
56 women with normal 
pregnancy
CRP and plasma pregnancy‑ 
associated plasma protein‑A 
(PAPP‑A)
higher levels of PAPP‑A and CRP and the presence of a 
good correlation between CRP and MAP in PE
Gandevani 
et al. (2012)[22]
Iran Longitudinal 778 pregnant women 
between 14‑20 weeks 
of gestation
hsCRP hsCRP can be useful in identifying pregnant women at 





40 normal pregnant 
women, 37 mild PE and 
38 severe PE women
hsCRP and sVCAM‑1 hsCRP is elevated in severe PE compared with mild PE 





50 normal pregnant 
women and 50 women 
with severe PE
IL‑6, TNF‑alpha and CRP IL6, TNF α and CRP are elevated in severe
preeclampsia and may mediate some of the clinical 





60 women with PE
60 women with normal 
pregnancy
hsCRP Elevated CRP levels in the preeclamptic pregnant women 
correlates with low fetal birth weight
Maged 
et al. (2017)[26]
Egypt Retrospective 90 patients each with 
normal pregnancy, mild 




Blood urea nitrogen, serum uric acid, CRP
alanine transaminase, and the platelet count were linked 





40 women with 
normal pregnancy, 12 
mild PE and 33 severe 
PE. All presenting for 





for evaluating uterine 
artery S/D ratio
hsCRP is significantly elevated in pre‑eclampsia. 
hsCRP along with blood pressure measurement 
and uric acid level can be used as an indicator 
of severity of pre‑eclampsia and predictor of the 
outcomes in late presenting pregnant women. 
However, hsCRP alone can’t be used for this 
purpose
Hypertension in Pregnancy[7] have recently suggested uric acid 
to be a useful parameter. We also found that uric acid levels 
correlate well with a decreased baby weight. Once the severity 
of PE has been predicted, additional attention can be given to the 
patient and due precautions taken to ensure optimal maternal 
and fetal outcomes.
This is the first study which evaluates the role of hsCRP as 
the sole investigation for predicting the severity and the 
outcome in women presenting very late in the third trimester. 
There were a few notable limitations. The small sample 
size especially of PE without severe features patients is a 
major factor. We believe that a study with a larger number 
of patients would be appropriate for clarifying the role of 
hsCRP as a predictor of severity and outcome of PE especially 
in patients presenting late in the third trimester.
Conclusion
hsCRP is significantly elevated in patients of pre-eclampsia (both 
with and without severe features) presenting very late in the 
Mishra, et al.: hsCRP as a sole investigation in pre‑eclampsia
60 Tropical Journal of Obstetrics and Gynaecology / Volume 36 / Issue 1 / January‑April 2019
third trimester. However, it solely can’t be used as an indicator 
of severity and predictor of outcome of PE. That being said, 
hsCRP along with serum uric acid can be used to predict the 
severity and outcome of pre-eclampsia presenting late in third 
trimester and the available resources can then be utilized 
better to provide optimum care to such patients.
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